Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.

Developed by Abcam for use by Merck as an analytical antibody to support Merck’s therapeutic program several years ago, this new clone has been created by Abcam’s in-house antibody engineers, who specialize in the discovery and development of challenging antibodies. The antibody is important in assessing the expression of PD-L1 in tumors from patients who might be able to benefit from PD-1/PD-L1 checkpoint immunotherapy.

John Baker, senior vice president, Portfolio and Business Development, Abcam said, “Collaborations with industry partners are an important part of Abcam’s strategy to provide the best tools to all researchers world-wide. By working with Merck we are able to make available this important antibody at scale to help scientists accelerate their research, and expand understanding of the role of immune checkpoint inhibitors as cancer therapeutics.”

Clone 73-10 is an important addition to Abcam’s range of PD-1/PD-L1 immune checkpoint antibodies and is available via the Abcam website. To find out more please visit www.abcam.com/pdl1-ab-73-10.